United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.59 USD
-5.15 (-1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $331.56 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 581 - 598 ( 598 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Financials Beat Due To Strong Product Sales. Raising Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: We Believe Q3 Consensus Is A Bit High. However, Since UTHR Is Trading In-Line, We Anticipate A Small Miss Won?t Be Material.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Financials Beat: Lower Operating Expenses And Strong Adcirca Sales Led To GAAP EPS Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Believe Q2 Consensus Is Somewhat High. However, Since UTHR Is Trading In-Line With Comparables, We Don?t Expect A Small Miss To Be Material.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Accelerates Top-Line Growth.
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials Beat: Tyvaso Strength Was Understandable But Is Remodulin?s Q1 Strength Sustainable?
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Think Q1 Will Be Either In-Line Or Squeak By Consensus--Tyvaso Is The Wild Card.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Uptake Looks Strong - Reiterate Buy.
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
In Response To The Tyvaso MAA Withdrawal, We Are Lowering Our Fair Value to $59 But Maintaining Our NEUTRAL Rating.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Robust Quarter - Reiterating Buy
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Revenues Slightly Beat Our and Consensus Estimates but GAAP EPS Missed on Higher Operating Expenses
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Although We Raised Our Q4 Estimates, Consensus Is Still Relatively High. Even So, We Believe Investors Are Focused On Better Than Expected Product Launches
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L